当前位置:首页 - 行情中心 - 第一医药(600833) - 财务分析 - 利润表

第一医药

(600833)

  

流通市值:28.35亿  总市值:28.35亿
流通股本:2.23亿   总股本:2.23亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入503,963,782.81,915,159,154.271,368,880,300.43893,171,191.53
营业收入503,963,782.81,915,159,154.271,368,880,300.43893,171,191.53
二、营业总成本497,905,553.681,908,589,189.921,367,026,359.88891,988,686.49
营业成本418,553,990.571,596,660,714.131,140,076,016.83743,347,007.66
税金及附加1,659,098.465,879,527.544,125,527.362,389,071.35
销售费用66,467,454.03252,304,833.4191,832,654.92126,660,847.22
管理费用13,323,616.0667,764,721.7641,681,103.0926,805,293.97
财务费用-2,098,605.44-14,020,606.91-10,688,942.32-7,213,533.71
其中:利息费用1,364,504.466,049,917.484,510,224.262,935,074.3
其中:利息收入3,545,859.4220,956,663.7617,145,95711,697,296.47
加:公允价值变动收益-379,109.59--
加:投资收益580,197.2812,905,483.2310,739,697.338,795,169.67
资产处置收益29,143.12169,174,142.38140,908,008.63140,050,836.52
资产减值损失(新)--4,789,484.62--
信用减值损失(新)-23,300,492.52-270,036-270,036
其他收益175,681.26532,275.27415,914.24281,735.09
营业利润平衡项目0000
四、营业利润6,843,250.78208,071,982.72153,647,524.75150,040,210.32
加:营业外收入28,607.1211,268,736.4641,208,224.8121,310,491.1
减:营业外支出488,759.543,069,455.62884,283.12758,716.83
利润总额平衡项目0000
五、利润总额6,383,098.36216,271,263.56193,971,466.44170,591,984.59
减:所得税费用1,579,619.0752,655,904.646,613,373.7440,877,261.81
六、净利润4,803,479.29163,615,358.96147,358,092.7129,714,722.78
持续经营净利润4,803,479.29163,615,358.96147,358,092.7129,714,722.78
归属于母公司股东的净利润4,739,088.09163,061,272.77147,324,925.33129,789,131.26
少数股东损益64,391.2554,086.1933,167.37-74,408.48
(一)基本每股收益0.020.730.660.58
(二)稀释每股收益0.020.730.660.58
八、其他综合收益-464,615.21-1,354,766.19-698,050.74-19,500,998.78
归属于母公司股东的其他综合收益-464,615.21-1,354,766.19-698,050.74-19,500,998.78
九、综合收益总额4,338,864.08162,260,592.77146,660,041.96110,213,724
归属于母公司股东的综合收益总额4,274,472.88161,706,506.58146,626,874.59110,288,132.48
归属于少数股东的综合收益总额64,391.2554,086.1933,167.37-74,408.48
公告日期2025-04-302025-04-092024-10-312024-08-31
审计意见(境内)标准无保留意见
TOP↑